These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 27481775)

  • 1. Selectivity of BI 689648, a Novel, Highly Selective Aldosterone Synthase Inhibitor: Comparison with FAD286 and LCI699 in Nonhuman Primates.
    Weldon SM; Cerny MA; Gueneva-Boucheva K; Cogan D; Guo X; Moss N; Parmentier JH; Richman JR; Reinhart GA; Brown NF
    J Pharmacol Exp Ther; 2016 Oct; 359(1):142-50. PubMed ID: 27481775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aldosterone synthase inhibition in humans.
    Azizi M; Amar L; Menard J
    Nephrol Dial Transplant; 2013 Jan; 28(1):36-43. PubMed ID: 23045428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic and pharmacokinetic characterization of the aldosterone synthase inhibitor FAD286 in two rodent models of hyperaldosteronism: comparison with the 11beta-hydroxylase inhibitor metyrapone.
    Rigel DF; Fu F; Beil M; Hu CW; Liang G; Jeng AY
    J Pharmacol Exp Ther; 2010 Jul; 334(1):232-43. PubMed ID: 20354176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Aldosterone Synthase Inhibitor FAD286 is Suitable for Lowering Aldosterone Levels in ZDF Rats but not in db/db Mice.
    Hofmann A; Brunssen C; Peitzsch M; Balyura M; Mittag J; Frenzel A; Jannasch A; Brown NF; Weldon SM; Gueneva-Boucheva KK; Eisenhofer G; Bornstein SR; Morawietz H
    Horm Metab Res; 2017 Jun; 49(6):466-471. PubMed ID: 28427090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aldosterone synthase inhibition: cardiorenal protection in animal disease models and translation of hormonal effects to human subjects.
    Ménard J; Rigel DF; Watson C; Jeng AY; Fu F; Beil M; Liu J; Chen W; Hu CW; Leung-Chu J; LaSala D; Liang G; Rebello S; Zhang Y; Dole WP
    J Transl Med; 2014 Dec; 12():340. PubMed ID: 25491597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rhesus monkey model for concurrent analyses of in vivo selectivity, pharmacokinetics and pharmacodynamics of aldosterone synthase inhibitors.
    Cai TQ; Stribling S; Tong X; Xu L; Wisniewski T; Fontenot JA; Struthers M; Akinsanya KO
    J Pharmacol Toxicol Methods; 2015; 71():137-46. PubMed ID: 25304940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism.
    Amar L; Azizi M; Menard J; Peyrard S; Watson C; Plouin PF
    Hypertension; 2010 Nov; 56(5):831-8. PubMed ID: 20837883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of Aldosterone Synthase.
    Weldon SM; Brown NF
    Vitam Horm; 2019; 109():211-239. PubMed ID: 30678857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Aldosterone Synthase Inhibitor FAD286 on Steroid Hormone Profile in Human Adrenocortical Cells.
    Brunssen C; Hofmann A; Peitzsch M; Frenzel A; Ziegler CG; Brown NF; Weldon SM; Eisenhofer G; Willenberg HS; Bornstein SR; Morawietz H
    Horm Metab Res; 2017 Sep; 49(9):701-706. PubMed ID: 28759940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of 3-Pyridyl Isoindolin-1-one Derivatives as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors.
    Liu Y; Wu J; Zhou M; Chen W; Li D; Wang Z; Hornsperger B; Aebi JD; Märki HP; Kuhn B; Wang L; Kuglstatter A; Benz J; Müller S; Hochstrasser R; Ottaviani G; Xin J; Kirchner S; Mohr S; Verry P; Riboulet W; Shen HC; Mayweg AV; Amrein K; Tan X
    J Med Chem; 2020 Jul; 63(13):6876-6897. PubMed ID: 32530624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of N-[5-(6-Chloro-3-cyano-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, a Cortisol-Sparing CYP11B2 Inhibitor that Lowers Aldosterone in Human Subjects.
    Papillon JP; Lou C; Singh AK; Adams CM; Ksander GM; Beil ME; Chen W; Leung-Chu J; Fu F; Gan L; Hu CW; Jeng AY; LaSala D; Liang G; Rigel DF; Russell KS; Vest JA; Watson C
    J Med Chem; 2015 Dec; 58(23):9382-94. PubMed ID: 26540564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A patent review of aldosterone synthase inhibitors (2014-present).
    Wu J; Ding X; Tan X
    Expert Opin Ther Pat; 2022 Jan; 32(1):13-28. PubMed ID: 34365871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aldosterone Synthase Inhibition Improves Glucose Tolerance in Zucker Diabetic Fatty (ZDF) Rats.
    Hofmann A; Brunssen C; Peitzsch M; Martin M; Mittag J; Jannasch A; Engelmann F; Brown NF; Weldon SM; Huber J; Streicher R; Deussen A; Eisenhofer G; Bornstein SR; Morawietz H
    Endocrinology; 2016 Oct; 157(10):3844-3855. PubMed ID: 27526033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldosterone synthase inhibitors for cardiovascular diseases: A comprehensive review of preclinical, clinical and in silico data.
    Lenzini L; Zanotti G; Bonchio M; Rossi GP
    Pharmacol Res; 2021 Jan; 163():105332. PubMed ID: 33271294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel pyridyl- or isoquinolinyl-substituted indolines and indoles as potent and selective aldosterone synthase inhibitors.
    Yin L; Hu Q; Emmerich J; Lo MM; Metzger E; Ali A; Hartmann RW
    J Med Chem; 2014 Jun; 57(12):5179-89. PubMed ID: 24899257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical and Early Clinical Profile of a Highly Selective and Potent Oral Inhibitor of Aldosterone Synthase (CYP11B2).
    Bogman K; Schwab D; Delporte ML; Palermo G; Amrein K; Mohr S; De Vera Mudry MC; Brown MJ; Ferber P
    Hypertension; 2017 Jan; 69(1):189-196. PubMed ID: 27872236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neovascularization is attenuated with aldosterone synthase inhibition in rats with retinopathy.
    Deliyanti D; Miller AG; Tan G; Binger KJ; Samson AL; Wilkinson-Berka JL
    Hypertension; 2012 Mar; 59(3):607-13. PubMed ID: 22275532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of 4-Aryl-5,6,7,8-tetrahydroisoquinolines as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors: In Vivo Evaluation in Rodents and Cynomolgus Monkeys.
    Martin RE; Aebi JD; Hornsperger B; Krebs HJ; Kuhn B; Kuglstatter A; Alker AM; Märki HP; Müller S; Burger D; Ottaviani G; Riboulet W; Verry P; Tan X; Amrein K; Mayweg AV
    J Med Chem; 2015 Oct; 58(20):8054-65. PubMed ID: 26403853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-Activity Relationships, Pharmacokinetics, and in Vivo Activity of CYP11B2 and CYP11B1 Inhibitors.
    Papillon JP; Adams CM; Hu QY; Lou C; Singh AK; Zhang C; Carvalho J; Rajan S; Amaral A; Beil ME; Fu F; Gangl E; Hu CW; Jeng AY; LaSala D; Liang G; Logman M; Maniara WM; Rigel DF; Smith SA; Ksander GM
    J Med Chem; 2015 Jun; 58(11):4749-70. PubMed ID: 25953419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of sulfonylpyrimidines as novel selective aldosterone synthase (CYP11B2) inhibitors.
    Meguro M; Miyauchi S; Kanao-Arisumi Y; Naito S; Suzuki K; Inoue S; Yamada K; Homma T; Chiba K; Nara F; Furuzono S
    Bioorg Med Chem; 2024 Jun; 108():117775. PubMed ID: 38851000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.